ANTX
Price
$1.26
Change
-$0.00 (-0.00%)
Updated
Sep 5 closing price
Capitalization
34.43M
59 days until earnings call
PHAR
Price
$15.26
Change
+$0.39 (+2.62%)
Updated
Sep 5 closing price
Capitalization
1.03B
59 days until earnings call
Interact to see
Advertisement

ANTX vs PHAR

Header iconANTX vs PHAR Comparison
Open Charts ANTX vs PHARBanner chart's image
AN2 Therapeutics
Price$1.26
Change-$0.00 (-0.00%)
Volume$37.93K
Capitalization34.43M
Pharming Group
Price$15.26
Change+$0.39 (+2.62%)
Volume$21.45K
Capitalization1.03B
ANTX vs PHAR Comparison Chart in %
Loading...
ANTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHAR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANTX vs. PHAR commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANTX is a Hold and PHAR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (ANTX: $1.26 vs. PHAR: $15.26)
Brand notoriety: ANTX and PHAR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANTX: 46% vs. PHAR: 230%
Market capitalization -- ANTX: $34.43M vs. PHAR: $1.03B
ANTX [@Biotechnology] is valued at $34.43M. PHAR’s [@Biotechnology] market capitalization is $1.03B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANTX’s FA Score shows that 1 FA rating(s) are green whilePHAR’s FA Score has 1 green FA rating(s).

  • ANTX’s FA Score: 1 green, 4 red.
  • PHAR’s FA Score: 1 green, 4 red.
According to our system of comparison, both ANTX and PHAR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANTX’s TA Score shows that 6 TA indicator(s) are bullish while PHAR’s TA Score has 5 bullish TA indicator(s).

  • ANTX’s TA Score: 6 bullish, 4 bearish.
  • PHAR’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ANTX is a better buy in the short-term than PHAR.

Price Growth

ANTX (@Biotechnology) experienced а +14.55% price change this week, while PHAR (@Biotechnology) price change was +2.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

ANTX is expected to report earnings on Nov 06, 2025.

PHAR is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHAR($1.03B) has a higher market cap than ANTX($34.4M). PHAR YTD gains are higher at: 51.615 vs. ANTX (-8.696). PHAR has higher annual earnings (EBITDA): 29.5M vs. ANTX (-39.13M). PHAR has more cash in the bank: 126M vs. ANTX (62.9M). PHAR has higher revenues than ANTX: PHAR (340M) vs ANTX (0).
ANTXPHARANTX / PHAR
Capitalization34.4M1.03B3%
EBITDA-39.13M29.5M-133%
Gain YTD-8.69651.615-17%
P/E RatioN/AN/A-
Revenue0340M-
Total Cash62.9M126M50%
Total DebtN/A128M-
FUNDAMENTALS RATINGS
ANTX: Fundamental Ratings
ANTX
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
11
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
46
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
56

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ANTXPHAR
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
86%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
70%
MACD
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
66%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
68%
Advances
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 3 days ago
67%
Declines
ODDS (%)
Bearish Trend 11 days ago
84%
Bearish Trend 26 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
Aroon
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 5 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ANTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHAR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PRDSX46.380.25
+0.54%
T. Rowe Price Integrated US Sm Gr Eq
PXSAX18.490.07
+0.38%
Impax Small Cap A
CYPSX60.71-0.01
-0.02%
ProFunds Consumer Disctnry Ultra Sec Svc
JDPNX16.26-0.01
-0.06%
Janus Henderson Mid Cap Value N
EGLCX10.25-0.11
-1.06%
Eagle Energy Infrastructure C

ANTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANTX has been loosely correlated with ROIV. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ANTX jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANTX
1D Price
Change %
ANTX100%
N/A
ROIV - ANTX
35%
Loosely correlated
+2.78%
SNBIF - ANTX
33%
Loosely correlated
N/A
PASG - ANTX
32%
Poorly correlated
+2.57%
AVXL - ANTX
29%
Poorly correlated
+0.43%
PHAR - ANTX
28%
Poorly correlated
+2.62%
More

PHAR and

Correlation & Price change

A.I.dvisor tells us that PHAR and ANTX have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PHAR and ANTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAR
1D Price
Change %
PHAR100%
+2.62%
ANTX - PHAR
28%
Poorly correlated
N/A
IBRX - PHAR
27%
Poorly correlated
+0.42%
IMMP - PHAR
24%
Poorly correlated
+1.85%
VERU - PHAR
22%
Poorly correlated
+2.12%
CTXR - PHAR
22%
Poorly correlated
+6.96%
More